Skip to main content
. 2016 Oct 12;7(46):76006–76020. doi: 10.18632/oncotarget.12579

Figure 3. IL-23 is required for self-renewal capacity of CD133+ CSLCs.

Figure 3

A. A2780-derived CD133+ cells were dissociated into 100 and 1 cells and stimulated by different concentrations of IL-23p19 neutralizing antibody for 6 and 20 days. The number and size of spheres were measured. B. Control shRNA (vector) or IL-23p19-shRNA transfected CD133+ A2780 cells were dissociated in 100 and 1 cells and incubated for 7 and 15 days. The number and size of spheres were measured. C, D. A2780-derived (C) and SKOV3-dereved (D) CD133+ cells were dissociated into 100 and 1 cells and stimulated by different concentrations of IL-23 inhibitor STA-5326 for 5 and 15 days. The number and size of spheres were measured. All experiments were performed three times and data are expressed as mean ± SD. *P<0.05, **P<0.01, ***P<0.001.